Background-We examined whether the antiinflammatory action of statins may be of benefit in heart failure, a state characterized by inflammation in which low cholesterol is associated with worse outcomes. Methods and Results-We compared 10 mg rosuvastatin daily with placebo in patients with ischemic systolic heart failure according to baseline high sensitivity-C reactive protein (hs-CRP) Ͻ2.0 mg/L (placebo, nϭ779; rosuvastatin, nϭ777) or Ն2.0 mg/L (placebo, nϭ1694; rosuvastatin, nϭ1711). The primary outcome was cardiovascular death, myocardial infarction, or stroke. Baseline low-density lipoprotein was the same, and rosuvastatin reduced low-density lipoprotein by 47% in both hs-CRP groups. Median hs-CRP was 1.10 mg/L in the lower and 5.60 mg/L in the higher hs-CRP group, with higher hs-CRP associated with worse outcomes. The change in hs-CRP with rosuvastatin from baseline to 3 months was Ϫ6% in the low hs-CRP group (27% with placebo) and Ϫ33.3% in the high hs-CRP group (Ϫ11.1% with placebo). In the high hs-CRP group, 548 placebo-treated (14.0 per 100 patient-years of follow-up) and 498 rosuvastatin-treated (12.2 per 100 patient-years of follow-up) patients had a primary end point (hazard ratio of placebo to rosuvastatin, 0.87; 95% confidence interval, 0.77 to 0.98; Pϭ0.024). In the low hs-CRP group, 175 placebo-treated (8.9 per 100 patient-years of follow-up) and 188 rosuvastatin-treated (9.8 per 100 patient-years of follow-up) patients experienced this outcome (hazard ratio, 1.09; 95% confidence interval, 0.89 to 1.34; PϾ0.2; P for interactionϭ0.062). The numbers of deaths were as follows: 581 placebo-treated (14.1 per 100 patient-years of follow-up) and 532 rosuvastatin-treated (12.6 per 100 patient-years) patients in the high hs-CRP group (hazard ratio, 0.89; 95% confidence interval, 0.79 to 1.00; Pϭ0.050) and 170 placebo-treated (8.3 per 100 patient-years) and 192 rosuvastatin-treated (9.7 per 100 patient-years) patients in the low hs-CRP group (hazard ratio, 1.
I n addition to reducing low-density lipoprotein (LDL) cholesterol, statins have an antiinflammatory action. [1] [2] [3] How much of the benefit of statins, if any, is due to this antiinflammatory action is uncertain. [1] [2] [3] [4] [5] [6] 
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Inflammation is thought to play a role in the pathophysiology of heart failure. [7] [8] [9] [10] Inflammatory cytokines and other biomarkers such as high-sensitivity C-reactive protein (hs-CRP) are elevated in patients with heart failure and are predictive of worse clinical outcomes. [11] [12] [13] [14] Conversely, low cholesterol is an independent predictor of a poor prognosis in heart failure. 15, 16 Heart failure is therefore an inflammatory state in which the usual epidemiological relationship between cholesterol and cardiovascular outcomes is reversed and thus represents an excellent disease model in which to test the statin antiinflammatory hypothesis. 17, 18 Consequently, we examined outcomes in patients with heart failure in relation to baseline LDL cholesterol and hs-CRP concentrations and the effect of statin therapy according to these baseline measurements in patients in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). 19, 20 
Methods Patients
The design and principal findings of CORONA have been reported in detail. 19, 20 Patients Ն60 years of age with chronic New York Heart Association (NYHA) class II to IV heart failure of investigatorreported ischemic origin and an ejection fraction of Յ40% (Յ0.35 if NYHA class II) were eligible, provided that the investigator thought that they did not need treatment with a cholesterol-lowering drug. Exclusion criteria included recent cardiovascular events, procedures, or operations (or planned procedures or operations); acute or chronic liver disease or alanine aminotransferase Ͼ2.0 the upper limit of normal; serum creatinine Ͼ220 mol/L (Ͼ2.49 mg/dL); chronic muscle disease or unexplained creatine kinase Ͼ2.5 the upper limit of normal; thyroid-stimulating hormone Ͼ2 the upper limit of normal; and any other condition substantially reducing life expectancy.
Study Procedures
The trial was approved by the ethics committees of participating hospitals, and patients provided written informed consent. Eligible patients were treated with single-blind placebo for 2 to 4 weeks before randomization to demonstrate compliance. Randomization was based on an optimal assignment procedure, with a random element included. An optimally balanced allocation was achieved with the use of a score that included age; ejection fraction; NYHA class; the presence or absence of diabetes mellitus, myocardial infarction, or hypertension; the use of ␤-blockers; and total cholesterol. Patients were randomly assigned to receive 10 mg rosuvastatin or matching placebo once daily with the use of a centralized interactive Web-based response system (ClinPhone).
We measured serum creatinine, creatine kinase, thyroidstimulating hormone, alanine aminotransferase, hs-CRP, and lipid/ lipoproteins (total, LDL, and high-density lipoprotein [HDL] cholesterol; triglycerides; and apolipoprotein A-1 and B) at baseline in all patients. An immunonephelometric method was used to measure hs-CRP (Dade Behring BNII instrument using the CardioPhase hs-CRP reagent from Dade Behring, Deerfield, Ill; assay sensitivity, 0.040 mg/L; reference range, 0.0 to 8.4 mg/L).
After the study started, the protocol was amended to include measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP), which therefore was available in only 3664 patients (73%).
All measurements except thyroid-stimulating hormone were repeated at 3 months.
All blood samples were nonfasting and analyzed at a central laboratory (Medical Research Laboratories, Zaventem, Belgium). LDL was measured directly.
Study Outcomes and Definitions
The primary outcome was the composite of cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke, analyzed as time to the first event. The secondary outcomes were (in listed order) all-cause mortality, any coronary event (defined as sudden death, fatal or nonfatal myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, ventricular defibrillation by an implantable cardioverter-defibrillator, resuscitation from cardiac arrest, or hospitalization for unstable angina), cardiovascular mortality (cause-specific cardiovascular death was also analyzed), and total number (episodes) of hospitalizations (for cardiovascular causes, unstable angina, and worsening heart failure). We also included 1 additional posthoc composite outcome: death resulting from any cause or hospitalization for worsening heart failure, which is commonly reported in heart failure trials. The definition and adjudication of all outcomes have been described in detail previously. 19, 20 
Analysis of Outcomes According to Baseline hs-CRP
All study outcomes described above were analyzed according to whether baseline hs-CRP concentration was elevated (Ն2.0 mg/L) or not (ie, Ͻ2.0 mg/L). An hs-CRP threshold of 2.0 mg/L was chosen retrospectively on the basis of prior studies, was the entry criterion for the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), and was consistent with Centers for Disease Control/American Heart Association-recommended hs-CRP cut points. 6, [21] [22] [23] 
Statistical Analysis
For continuous variables, differences in baseline variables between the 2 hs-CRP subgroups were tested with the Student t test (for NT-proBNP, with the Wilcoxon test); for categorical variables, the Fisher exact test was used. Changes in median values over time were analyzed with the Wilcoxon test. Cox proportional-hazard models (unadjusted and adjusted) were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs; SAS version 8.2, SAS Institute, Inc, Cary, NC) in each hs-CRP group separately. The adjusted Cox regression model incorporated randomized treatment, baseline age (Ն75/Ͻ75 years), sex (female/male), ejection fraction (Ն0.25/ Ͻ0.25). NYHA class (III to IV/II), total cholesterol (Ն6.0/ Ͻ6.0 mmol/L), and history of diabetes mellitus (yes/no), myocardial infarction (yes/no), hypertension (yes/no), and ␤-blocker treatment at randomization (yes/no).
Tests for interaction between treatment and hs-CRP category for each outcome were carried out with Cox regression analysis with the following covariates: treatment as 0/1, hs-CRP subgroup (hs-CRP Ͻ2.0 versus Ն2.0 mg/L) as 0/1, and treatment-by-hs-CRP subgroup (interaction) as 0/1. Numbers of hospital admissions were analyzed with a permutation test.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Of the 5011 patients randomized between September 15, 2003, and April 21, 2005 , 4961 (99%) had a baseline measurement of hs-CRP. Of these, 1556 (779 placebo and 777 rosuvastatin; 31%) had a concentration Ͻ2.0 mg/L and 3405 (1694 placebo and 1711 rosuvastatin; 69%) had a concentration Ն2.0 mg/L. 
Patients
Patients with an hs-CRP Ն2.0 mg/L had more advanced heart failure as evidenced by worse NYHA class, more atrial fibrillation/flutter, higher NT-proBNP concentration, and worse renal function (Table 1 ). More patients with an elevated hs-CRP had diabetes mellitus and were current smokers (11.6% versus 8.2%). More patients with a high hs-CRP were treated with a diuretic and with digitalis at baseline. The characteristics of patients randomized to placebo and rosuvastatin within the 2 hs-CRP subgroups were very similar.
Baseline Lipids and hs-CRP
Baseline LDL cholesterol, HDL cholesterol, and triglycerides were similar in the 2 hs-CRP subgroups ( Table 2) . Baseline median hs-CRP was 1.10 mg/L in the lower hs-CRP group and 5.60 mg/L in the higher hs-CRP group.
Change in LDL Cholesterol and hs-CRP With Randomized Therapy
LDL cholesterol was reduced to a similar extent by rosuvastatin in both hs-CRP subgroups (placebo-corrected percent median change from baseline to 3 months, Ϫ47%; Table 2 ). Rosuvastatin-induced changes in HDL and triglycerides were also similar in the 2 hs-CRP subgroups.
Baseline hs-CRP was similar in the placebo-and rosuvastatin-treated patients in the lower hs-CRP subgroup (median, 1.10 mg/L in both treatment arms). The baseline hs-CRP was also similar in both treatment arms in the higher hs-CRP subgroup (5.70 mg/L in placebo group, 5.50 mg/L in the rosuvastatin group). Data at the 3-month follow-up visit are given in Table 2 . In placebo-treated patients, hs-CRP tended to rise in the low hs-CRP subgroup and fall in the high hs-CRP subgroup, suggesting regression to the mean. At 3 months, the median reduction in hs-CRP from baseline with rosuvastatin was Ϫ6% in the low hs-CRP group (compared with a 27% rise in the placebo group) and Ϫ33.3% in the high hs-CRP group (compared with an 11.1% reduction in the placebo group); ie, the net placebo-rosuvastatin difference in hs-CRP was similar in the high and low hs-CRP subgroups.
Primary Outcome
Patients with an hs-CRP concentration Ն2.0 mg/L had a higher rate of the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (14.0 events per 100 patient-years of follow-up in the placebo group) compared with patients with an hs-CRP concentration Ͻ2.0 mg/L (8.9 per 100 patient-years). Compared with placebo, treatment with rosuvastatin was associated with a reduced incidence of the primary outcome in the higher hs-CRP group (unadjusted HR, 0.87; 95% CI, 0.77 to 0.98; Pϭ0.024) but not in the lower hs-CRP group (HR, 1.09; 95% CI, 0.89 to 1.34; PϾ0.2; test for interaction by treatment, Pϭ0.062; Figure 1 ). The HR for rosuvastatin to placebo was not altered significantly after adjustment for important prognostic variables (see Methods; Cox-adjusted HR is shown in Figure 2 and the online-only Data Supplement).
Total Mortality
All-cause mortality was also higher in patients with an hs-CRP Ն2.0 mg/L (14.1 per 100 patient-years) compared with those with a lower hs-CRP (8.3 per 100 patient-years). Compared with placebo, rosuvastatin treatment was associated with a lower incidence of death in the elevated hs-CRP subgroup (HR, 0.89; 95% CI, 0.79 to 1.00; Pϭ0.050) compared with those with an hs-CRP Ͻ2.0 mg/L (HR, 1.17; 95% CI, 0.95 to 1.43; Pϭ0.14; test for interaction by treatment, Pϭ0.026; Cox-adjusted HR is shown in Figure 2 and the online-only Data Supplement).
Coronary Outcome
The rate of coronary events was higher in the group with an hs-CRP Ն2.0 mg/L (11.3 per 100 patient-years) than in patients with an hs-CRP Ͻ2.0 mg/L (7.5 per 100 patientyears). Compared with placebo, rosuvastatin treatment was associated with a lower incidence of coronary events in the elevated hs-CRP subgroup (HR, 0.85; 95% CI, 0.74 to 0.97; Pϭ0.017) compared with patients with an hs-CRP Ͻ2.0 mg/L (HR, 1.15; 95% CI, 0.92 to 1.43; PϾ0.2; test for interaction by treatment, Pϭ0.023; Cox-adjusted HR is shown in Figure 2 and the online-only Data Supplement).
All-Cause Mortality or Hospitalization for Worsening Heart Failure
The incidence of the composite outcome of death from any cause or hospitalization for worsening heart failure was higher in patients with an hs-CRP Ն2.0 mg/L than in patients with a lower hs-CRP. Compared with placebo, rosuvastatin treatment was associated with fewer events in patients with a higher hs-CRP (HR, 0.87; 95% CI, 0.79 to 0.96; Pϭ0.0049) compared with those with a lower hs-CRP (HR, 1.12; 95% CI, 0.95 to 1.33; PϾ0.2; P for interactionϭ0.011; Coxadjusted HR is shown in Figure 2 and the online-only Data Supplement). Table 3 presents cause-specific data for the total number of patients hospitalized (time to first event) and for the prespecified secondary end points of total number (episodes) of hospitalizations for cardiovascular reasons and for worsening heart failure. Regardless of cause, rates were higher in patients with a higher hs-CRP. Compared with placebo, rosuvastatin treatment was associated with fewer total hospitalizations for a cardiovascular reason (PϽ0.001) and for worsening heart failure (Pϭ0.004) in the subgroup with an hs-CRP Ն2.0 mg/L but not in the lower hs-CRP group ( Table 3) .
Hospitalizations

Discontinuation of Study Medicine
In those with hs-CRP Ն2.0 mg/L, 400 patients on placebo and 346 patients on rosuvastatin stopped randomized therapy (HR, 0.83; 95% CI, 0.72 to 0.96; Pϭ0.011). In 220 and 168 patients, respectively, this was due to an adverse event (HR, 0.73; 95% CI, 0.60 to 0.90; Pϭ0.0023). The corresponding numbers in those with hs-CRP Ͻ2.0 mg/L were 144 and 139 patients (HR, 0.98; 95% CI, 0.77 to 1.23; PϾ0.2) and 82 and 69 patients (HR, 0.85; 95% CI, 0.62 to 1.17; PϾ0. 2) . No category of adverse effects was found to be more common in the rosuvastatin group in either hs-CRP subgroup. Muscle symptoms, sought by active questioning or reported as adverse event, and elevations in creatinine kinase were not more common in any rosuvastatin hs-CRP subgroup (data not shown).
Discussion
We found that the effect of rosuvastatin in patients with advanced, ischemic, systolic heart failure was modified by baseline hs-CRP concentration. Specifically, we found a statistically significant interaction between the effect of rosuvastatin on most of the clinical outcomes and hs-CRP dichotomized at 2.0 mg/L. We chose an hs-CRP cut point of 2.0 mg/L because it was used in prior studies, was an entry criterion in JUPITER, and is consistent with the Centers for Disease Control/AHA recommendations. 6, [21] [22] [23] In patients with an hs-CRP Ն2.0 mg/L, compared with placebo, treatment with rosuvastatin was associated with a lower risk of patients experiencing a number of cardiovascular composite outcomes. Importantly, our findings could not be explained by LDL cholesterol (or any other lipid) levels. LDL cholesterol concentration was identical in both hs-CRP subgroups at baseline and was reduced by an identical amount compared with placebo in both hs-CRP subgroups (net placebo-corrected percent median difference, Ϫ47%).
What did differ between the hs-CRP subgroups was hs-CRP, which, by definition, was higher in the subgroup Ն2.0 mg/L at baseline. Consequently, any difference in the effect of rosuvastatin on clinical outcomes in these 2 subgroups was more likely to have been related to hs-CRP (or factors associated with hs-CRP) than lipids.
The number of deaths from any cause and the number of hospitalizations from any cause were also lower in rosuvastatin-treated compared with placebo-treated patients in the hs-CPR Ն2.0 mg/L subgroup. These differences were accounted for entirely by cardiovascular events, with no difference in noncardiovascular deaths or hospitalizations. Inflammation has been postulated to play a key pathophysiological role in atherothrombotic events such as acute coronary syndromes and stroke. 1, 2, 5, 6, 21, 22 These events, however, were relatively uncommon in our patient population. Despite this, rosuvastatin treatment was still associated with a reduction in cardiovascular hospitalizations, including hospitalizations for worsening heart failure. This finding suggests that inflammation may play a role in the progression of pump failure and in other types of cardiovascular events. [7] [8] [9] [10] [11] [12] [13] [14] Although the findings of retrospective subgroup analyses must always be treated with caution, our observations are in keeping with prior posthoc analyses of other trials and the results of the prospective JUPITER. 5, 6, 21, 23 In both a primary prevention 5 and a secondary prevention 4 coronary heart disease trial, statin treatment was associated with greater event reduction in patients with a higher hs-CRP than in those with a lower hs-CRP. Notably, and in keeping with our findings, a retrospective subgroup analysis of the Air Force/ Texas Coronary Atherosclerosis Prevention study showed that lovastatin had no impact on vascular events in patients with an LDL cholesterol Ͻ150 mg/dL and hs-CRP Ͻ2.0 mg/L but did appear to reduce events in those with an LDL Ͻ150 mg/dL but hs-CRP Ͼ2.0 mg/L (with similar LDL reductions in each hs-CRP subgroup). 5 In an acute coronary syndrome trial, patients with an hs-CRP Ͻ2.0 mg/L after statin treatment had a better outcome than those with an hs-CRP concentration Ն2.0 mg/L. 6 Recently, JUPITER, which studied the effect of rosuvastatin 20 mg/d compared with placebo in healthy individuals with low LDL cholesterol levels (Ͻ3.36 mmol/L [130 mg/dL]) but an hs-CRP Ն2.0 mg/L, was stopped prematurely because of benefit. 23 A further analysis of outcomes by on-treatment concentrations of hs-CRP (split, Ͻ2.0 versus Ն2.0 mg/L) in JUPITER showed that achievement of an hs-CRP concentration of Ͻ2.0 mg/L was associated with improved event-free survival compared with achievement of a low LDL cholesterol alone. 24 Although these external data support the validity of our findings, our results must be regarded as hypothesis generating only, especially because there was no effect of rosuvastatin overall on either the primary outcome or allcause mortality.
Although treatment with rosuvastatin appeared to be associated with better cardiovascular outcomes in the subgroup with an hs-CRP Ն2.0 mg/L at baseline, there were weak trends to worse cardiovascular outcomes in the subgroup with an hs-CRP Ͻ2.0 mg/L at baseline. Whether these observations reflect the play of chance or whether statins could be harmful in patients with heart failure and a low hs-CRP is uncertain. The slight excess of deaths in rosuvastatin-treated patients in the low hs-CRP subset (170 on placebo, 192 on rosuvastatin) was wholly accounted for by numerically more cardiovascular deaths (with more of each of the 2 main types of cardiovascular death [ie, sudden death and death caused by pump failure]). However, examination of hospitalizations did not reveal any clear pattern of harm. Although the number of patients admitted with worsening heart failure was increased somewhat in the rosuvastatin group, there was no excess in the total number (episodes) of heart failure hospitalization in the rosuvastatin group or in the number of patients hospitalized for a cardiovascular reason. Consequently, there was no strong evidence of increased risk of any particular type of cardiovascular event with rosuvastatin in the low hs-CRP subgroup. Rosuvastatin also appeared to be well tolerated in the low hs-CRP subgroup, as assessed by discontinuation of study drug. Nevertheless, the possibility that statins could be harmful in certain subsets of patients with heart failure remains, particularly in light of the association of poorer outcomes with lower cholesterol in this syndrome. [15] [16] [17] [18] Although we have interpreted the apparently beneficial effect of rosuvastatin in patients with a raised hs-CRP to reflect an antiinflammatory action, alternative explanations are possible. An elevated hs-CRP could represent an alternative pathophysiological process (eg, a prothrombotic state) or could be a marker of other patient factors that could be associated with a greater benefit from a statin. Conversely, an elevated hs-CRP may indicate a pathophysiological state in which LDL cholesterol is modified to become more toxic to the arteries (eg, where there is enhanced oxidative stress). Consequently, even though LDL concentration and LDL reduction with treatment are similar, arterial toxicity may be reduced more with a statin in patients with an elevated hs-CRP.
Conclusions
Our findings are consistent with prior data in healthy individuals that statin therapy may be more beneficial among those with increased hs-CRP and are novel in that they extend this concept to patients with congestive heart failure. However, this apparent therapeutic effect in patients with heart failure needs to be confirmed in a prospective randomized trial.
